Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRG | P62508 | 3/20 | 0.55 |
| ▸ | ESRRB | O95718 | 2/20 | 0.55 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | NQO2 | P16083 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.46 |
| ▸ | MIF | P14174 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17623638 | 0.94 | ESRRG (0.57) | ESRRGESRRBDGAT1EGFRNQO2 | |
| SCHEMBL5896700 | 0.88 | DGAT1 (0.53) | DGAT1EGFRNPC1GAAMAPT | |
| SCHEMBL5664574 | 0.88 | DGAT1 (0.50) | DGAT1EGFRNPC1GAARAB9A | |
| SCHEMBL12093593 | 0.88 | POLB (0.61) | DGAT1EGFRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3523655 | 0.87 | TDP1 (0.60) | NPC1GAARAB9AALDH1A1POLB | |
| SCHEMBL14158944 | 0.87 | ALDH1A1 (0.57) | DGAT1EGFRNPC1GAAMAPT | |
| SCHEMBL17918213 | 0.86 | DGAT1 (0.49) | DGAT1EGFRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10287615 | 0.86 | CYP1A2 (0.55) | DGAT1NPC1CYP1A2GAACYP2C19 | |
| SCHEMBL5663146 | 0.86 | DGAT1 (0.49) | DGAT1EGFRNPC1CYP1A2CYP2D6 | |
| SCHEMBL750337 | 0.86 | ESRRG (0.56) | ESRRGDGAT1EGFRMAPTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | TOPAZ THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-8138209-B2 | Substituted picolinamides as MAO-B inhibitors useful for treating obesity | JENRIN DISCOVERY, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138209-B2 | Substituted picolinamides as MAO-B inhibitors useful for treating obesity | JENRIN DISCOVERY, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| WO-2007008963-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-01-18 | — | — | WO | disclosed |
| US-20070015734-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-01-18 | — | — | US | disclosed |
| US-20070015734-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015734-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | ESRRG 1261/4885ESRRB 1158/4885DGAT1 354/4885 |
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | RIOX2, ORC3, DCLRE1A | ESRRG 411/4885ESRRB 327/4885DGAT1 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.